Castle Creek Biosciences, based in Exton, Pennsylvania, is a privately held biotech focused on developing and commercializing gene therapies for rare and serious genetic disorders. Its lead candidate, FCX-007, is in Phase 3 clinical development for recessive dystrophic epidermolysis bullosa (RDEB), the most severe form of epidermolysis bullosa. The company is also advancing CCP-020, a diacerein topical ointment for epidermolysis bullosa simplex and other EB subtypes, and FCX-013 for moderate to severe localized scleroderma. Funding is being directed toward expanding this gene therapy pipeline and enhancing the company’s current good manufacturing practices (cGMP) infrastructure in the greater Philadelphia region. Led by CEO John Maslowski, Castle Creek aims to transition its late-stage programs toward commercialization while bolstering in-house manufacturing capabilities. The recent capital infusion combines equity and venture debt, underscoring investor confidence in its clinical and manufacturing progress.

Total raised

$195M

Funding rounds

4

Latest round

Debt Financing

Latest activity

Mar 2020